European regulators validate Cempra's drug application

European regulators have validated an application by Chapel Hill drug developer Cempra (Nasdaq: CEMP), a move that formally starts the review process. Cempra has developed a new pneumonia treatment that is not susceptible to antibiotic resistance. These superbugs present a threat to modern medicine because antibiotics are used for many treatments. Cempra’s treatment, called solithromycin, has shown it is not susceptible to antibiotic resistan ce. The European Medicines Agency, Europe’s version…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news